title: Evaluation of expression of the PTEN gene, oestrogen and progesterone receptors as diagnostic and predictive factors in endometrial cancer.
abstract: Endometrial cancer belongs to the commonest malignancy in females after breast cancer, malignant neoplasm of female genitals in Europe and North America but there is still not significant improvement as far as the curability of this neoplasm is concerned, especially its advanced forms. That is why there is need to define new factors that could be not only diagnostic but also predictve factors. In present study we analyzed the mRNA PTEN expression by quantitative real-time polymerase chain reaction (Q-PCR) in 123 women of endometrial carcinoma and 14 women of control group. Moreover we assessed oestrogen (ER) and progesterone receptors (PgR) in all cases. We defined the correlation between expression of PTEN gene and receptors and between PTEN expression and maturity grade of cancer. Neoplasm advancement grade G1 was diagnosed in 82.11% of patients (n = 101), G2 in 9.76% of patients (n = 12) and G3 in 8.13% of patients (n = 10). Presence of ER and PgR and decreased expression of PTEN gene was found in majority of patients with endometrial cancer (79.12% and 59.34% respectively) and the most numerous group was with weak expression of ER and strong expression of PgR. There was no statistically significant difference in gene expression depending on receptors expression nor maturity grade of cancer (p > 0.05). Evaluation of expression of PTEN gene may turn out to be a very useful tool aimed at qualifying patients for different therapies of endometrial cancer and at searching of new diagnostic and therapeutic methods of this cancer independently on its receptor status nor maturity grade of cancer.
authors.affiliation: Cathedral of Mother's and Child's Health, Poznan University of Medical Sciences, ul. Polna 33, 60-535, Poznań, Poland.
authors.forename: Dariusz
authors.initials: D
authors.lastname: Samulak
authors.forename: Patrycja
authors.initials: P
authors.lastname: Grosman-Dziewiszek
authors.forename: Magdalena M
authors.initials: MM
authors.lastname: Michalska
authors.forename: Ewa
authors.initials: E
authors.lastname: Mojs
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Samulak
authors.forename: Hanna
authors.initials: H
authors.lastname: Romanowicz
authors.forename: Beata
authors.initials: B
authors.lastname: Smolarz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D005260:Female; D015870:Gene Expression; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis / Q000235:genetics*; D011960:Receptors, Estrogen / Q000096:biosynthesis / Q000235:genetics*; D011980:Receptors, Progesterone / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
references.citation: Pathology. 2007 Feb;39(1):46-54
references.pmid: 17365822
references.citation: J Natl Cancer Inst. 2000 Jun 7;92(11):924-30
references.pmid: 10841828
references.citation: J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):221-9
references.pmid: 18061438
references.citation: Curr Opin Obstet Gynecol. 2002 Feb;14(1):59-65
references.pmid: 11801878
references.citation: APMIS. 2002 Oct;110(10):673-89
references.pmid: 12583434
references.citation: Int J Oncol. 2004 Dec;25(6):1615-23
references.pmid: 15547698
references.citation: Crit Rev Clin Lab Sci. 2005;42(5-6):453-72
references.pmid: 16390681
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5932-5
references.pmid: 17062663
references.citation: Science. 2005 Feb 18;307(5712):1098-101
references.pmid: 15718470
references.citation: Cancer Res. 1997 Sep 15;57(18):3935-40
references.pmid: 9307275
references.citation: Obstet Gynecol Int. 2010;2010:162363
references.pmid: 20368795
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4783-91
references.pmid: 17028294
references.citation: Carcinogenesis. 2007 Jul;28(7):1379-86
references.pmid: 17341655
references.citation: Int J Cancer. 2001 Jan 1;91(1):22-6
references.pmid: 11149415
references.citation: Cancer Lett. 2006 Jul 8;238(1):61-8
references.pmid: 16085355
references.citation: Cancer Control. 2009 Jan;16(1):8-13
references.pmid: 19078924
references.citation: Oncol Rep. 2005 Jan;13(1):17-24
references.pmid: 15583796
references.citation: Clin Cancer Res. 2005 Apr 15;11(8):2875-8
references.pmid: 15837735
references.citation: Gynecol Endocrinol. 2008 May;24(5):239-49
references.pmid: 18569027
references.citation: Int J Gynecol Cancer. 2006 May-Jun;16(3):1412-8
references.pmid: 16803539
references.citation: Pathology. 2007 Feb;39(1):72-87
references.pmid: 17365824
references.citation: Cancer Res. 2005 Dec 1;65(23):10669-73
references.pmid: 16322209
references.citation: APMIS. 2009 Oct;117(10):693-707
references.pmid: 19775337
references.citation: Cancer Res. 1998 Jun 15;58(12):2500-3
references.pmid: 9635567
references.citation: Cancer Res. 2008 Aug 1;68(15):6084-91
references.pmid: 18676830
references.citation: Cancer Control. 2009 Jan;16(1):38-45
references.pmid: 19078928
references.citation: J Genet Couns. 2009 Feb;18(1):13-27
references.pmid: 18972196
references.citation: Virchows Arch. 2004 Mar;444(3):213-23
references.pmid: 14747944
references.citation: J Clin Pathol. 2009 Sep;62(9):777-85
references.pmid: 18977806
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: Eur J Cancer. 2010 May;46(8):1365-73
references.pmid: 20304627
references.citation: Pol J Pathol. 2006;57(3):137-40
references.pmid: 17219740
references.citation: Taiwan J Obstet Gynecol. 2007 Mar;46(1):26-32
references.pmid: 17389185
references.citation: Int J Cancer. 2005 Oct 20;117(1):123-31
references.pmid: 15880435
references.citation: Hum Pathol. 2001 Jun;32(6):569-77
references.pmid: 11431710